3.78
5.97%
-0.24
Revance Therapeutics Inc Stock (RVNC) Financials Data
Income Statement
Quarterly
*All numbers in millions
Period End Date | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 |
Period Length | 3 Months | 3 Months | 3 Months | 3 Months | 3 Months |
Revenues |
25.59%
51.94
|
69.80 | 56.78 | 58.13 | 49.33 |
Operating Expenses
|
20.19%
98.76
|
123.75 | 196.07 | 123.63 | 107.36 |
Interest Income/Expense |
2.63%
5.256
|
5.398 | 5.093 | 4.368 | 4.497 |
Benefits Costs and Expenses |
101.46
|
- | - | - | - |
Costs And Expenses |
18.01%
101.46
|
123.75 | 196.07 | 123.63 | 107.36 |
Depreciation and Amortization |
18.78%
0.545
|
0.671 | 1.32 | 2.135 | 2.004 |
Operating Income/Loss |
13.21%
-46.83
|
-53.95 | -139.29 | -65.50 | -58.03 |
Income/Loss From Continuing Operations Before Tax |
170.95%
-49.52
|
69.80 | 56.78 | 58.13 | 49.33 |
Income/Loss From Continuing Operations After Tax |
11.08%
-49.52
|
-55.70 | -141.18 | -67.32 | -59.79 |
Income/Loss From Discontinued Operations, Net Of Tax |
-3.627
|
- | - | - | - |
Net Income/Loss
|
4.57%
-53.15
|
-55.70 | -141.18 | -67.32 | -59.79 |
Preferred Stock Dividends And Other Adjustments |
-
|
- | - | - | - |
Attributable To Noncontrolling Interest |
-
|
- | - | - | - |
Basic Average Shares |
11,642%
91.92
|
0.7828 | 86.61 | 83.69 | 81.13 |
Diluted Average Shares |
11,642%
91.92
|
0.7828 | 86.61 | 83.69 | 81.13 |
Basic Earnings Per Share |
7.94%
-0.58
|
-0.63 | -1.63 | -0.80 | -0.74 |
Diluted Earnings Per Share |
7.94%
-0.58
|
-0.63 | -1.63 | -0.80 | -0.74 |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic |
-
|
- | - | - | - |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):